Delivery Order SPE2DB22D2211-SPE2DB24FNAR0
Award Date 3/20/24
Potential Completion Date 3/21/24
Potential Value $2.4K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit subsidiary of Amerisourcebergen Corporation, to provide Ondansetron HCl 8 mg tablets. The $4,310.25 contract has a completion date of February 23, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to deliver pharmaceuticals and...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,564,261 units of 8 mg ondansetron hydrochloride tablets in 30-count packaging. The $1,639.24 delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. This IDC serves as the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Ondansetron HCL 8 mg tablets in 30-count packages. The contract has a potential value of $29,504.32 and a completion date of February 5, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor supplying pharmaceutical products and medical supplies to DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) awarded a $6,533.85 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of the Amerisourcebergen Corporation. The contract is for the supply of 4,564,325,614 units of the prescription drug Ondansetron ODT 4 mg Tablet 30s. This delivery order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025....
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4 mg ondansetron hydrochloride tablets in unit dose packaging. The $1,912.25 delivery order has a completion date of February 20, 2024 and no set-aside designation. Amerisourcebergen Drug Corp is also the prime contractor on a separate $999,999,999.00 indefinite delivery contract with DLA to deliver a comprehensive range of...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Ondansetron HCL 4 mg tablets. The $1,667.12 contract has a completion date of February 6, 2024. Amerisourcebergen Drug Corp is the prime contractor and there are no set-aside designations indicated. This delivery order is issued under a larger indefinite delivery contract (IDC) with a potential...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of Ondansetron ODT 4 mg tablets. The order, valued at $3,672.70, has a completion date of February 1, 2024. Amerisourcebergen Drug Corp is the prime contractor and no set-aside designation was used. This delivery order is issued under a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug...
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,643,171 units of Ondansetron ODT 8 mg tablets in 30-count packages. The $2,239.95 contract has a completion date of February 14, 2024 and was awarded on February 13, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation for this award. This delivery order is part of a...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, through its Corporate Office division, a firm fixed price delivery order contract worth $1,222.69 for the supply of 4,564,095,638 units of Ondansetron HCL 4 MG tablets. The contract has an ultimate completion date of March 28, 2024. Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical sourcing and distribution company Amerisourcebergen Corporation, is the prime contractor. This delivery order is part...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Ondansetron ODT 4 mg tablets. The contract has a completion date of January 30, 2024 and a potential value of $6,528.94. Amerisourcebergen Drug Corp holds a larger indefinite delivery contract (IDC) with DLA with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. This IDC...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB24FNAR0Delivery Order
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4 mg ondansetron hydrochloride tablets in 30-count packages. The $2,436.56 contract has a performance period ending on March 21, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver pharmaceuticals and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. This delivery order is not associated with any set-aside designation.
Generated 6/19/24, 9:58 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 3/20/24 |